Apolipoprotein E enrichment of immuno-separated chylomicron and chylomicron remnants following saturated fatty acids.
OBJECTIVE
We examined the effect of meal fatty acids on lipid and apolipoprotein concentrations of very low density lipoprotein (VLDL) and chylomicron/chylomicron remnants in lipid fractions with a Svedberg flotation rate (Sf) 60-400 and Sf 20-60.


RESULTS
Six healthy middle-aged men received in random order mixed meals enriched with saturated (SFA), polyunsaturated (PUFA) or monounsaturated (MUFA) fatty acids on 3 occasions. VLDL and chylomicron/chylomicron remnants in the lipid fractions were separated by immunoaffinity chromatography against apo B-100. In the Sf 60-400 chylomicron/chylomicron remnants, triacylglycerol and cholesterol concentrations were significantly lower following PUFA compared with SFA and MUFA (P < or = 0.05). Apolipoprotein (apo) E responses were significantly higher after SFA in chylomicron/chylomicron remnants and VLDL compared with PUFA and MUFA (P < 0.007). However, apo B responses (particle number) were higher following MUFA than SFA (P = 0.039 for chylomicron/chylomicron remnants). Composition of the chylomicron/chylomicron remnants (expressed per particle) revealed differences in their triacylglycerol and apo E contents; in the Sf 60-400 fraction, SFA-rich chylomicron/chylomicron remnants contained significantly more triacylglycerol than MUFA (P = 0.028), more apo E than PUFA- and MUFA-rich particles (P < 0.05) and in the Sf 20-60 fraction, more apo E than MUFA (P = 0.009).


CONCLUSIONS
There are specific differences in the composition of chylomicron/chylomicron remnants formed after saturated compared with unsaturated fatty acid-rich meals which could determine their metabolic fate in the circulation and subsequent atherogenicity.
Jackson
Kim G
KG
Hugh Sinclair Unit of Human Nutrition, School of Food Biosciences, The University of Reading, Reading, Berkshire RG6 6AP, UK. k.g.jackson@reading.ac.uk
Wolstencroft
Emma J
EJ
Bateman
Paul A
PA
Yaqoob
Parveen
P
Williams
Christine M
CM
D000328:Adult; D053305:Apolipoprotein C-III; D001056:Apolipoproteins C / Q000032:analysis; D001057:Apolipoproteins E / Q000032:analysis*; D053298:Chylomicron Remnants; D002914:Chylomicrons / Q000032:analysis*; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage; D005215:Fasting / Q000097:blood; D005227:Fatty Acids / Q000008:administration & dosage*; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage; D006801:Humans; D008079:Lipoproteins, VLDL / Q000032:analysis; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D053305:Apolipoprotein C-III; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D053298:Chylomicron Remnants; D002914:Chylomicrons; D004042:Dietary Fats, Unsaturated; D005227:Fatty Acids; D005229:Fatty Acids, Monounsaturated; D005231:Fatty Acids, Unsaturated; D008079:Lipoproteins, VLDL; D014280:Triglycerides